These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25995772)

  • 1. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.
    Terawaki Y; Nomiyama T; Takahashi H; Tsutsumi Y; Murase K; Nagaishi R; Tanabe M; Kudo T; Kobayashi K; Yasuno T; Nakashima H; Yanase T
    Diabetol Metab Syndr; 2015; 7():44. PubMed ID: 25995772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
    Nakamura Y; Tsuji M; Hasegawa H; Kimura K; Fujita K; Inoue M; Shimizu T; Gotoh H; Goto Y; Inagaki M; Oguchi K
    Hemodial Int; 2014 Apr; 18(2):433-42. PubMed ID: 24405885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
    Han E; Lee M; Lee YH; Kim HS; Lee BW; Cha BS; Kang ES
    Diabetes Metab Syndr Obes; 2020; 13():4113-4121. PubMed ID: 33173319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study.
    Yoshizawa Y; Hosojima M; Kabasawa H; Tanabe N; Ugamura D; Koda Y; Shimada H; Takasawa T; Ito T; Kitamura T; Kobayashi M; Suzuki Y; Narita I; Saito A
    Diabetes Ther; 2021 Mar; 12(3):655-667. PubMed ID: 33474645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
    Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
    World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study.
    Hamasaki H; Hamasaki Y
    World J Diabetes; 2018 Oct; 9(10):165-171. PubMed ID: 30364744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
    Gallwitz B
    Ther Clin Risk Manag; 2015; 11():799-805. PubMed ID: 25999728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.
    Forst T; Pfützner A
    Expert Rev Endocrinol Metab; 2013 Jan; 8(1):21-35. PubMed ID: 30731650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
    Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.
    Hoimark L; Laursen T; Rungby J
    Diabetes Metab Syndr Obes; 2012; 5():295-302. PubMed ID: 22952411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
    Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen NM; Jandeleit-Dahm KA
    Diab Vasc Dis Res; 2019 Jul; 16(4):303-309. PubMed ID: 31018682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
    Gallwitz B
    Clin Med Insights Endocrinol Diabetes; 2012; 5():1-11. PubMed ID: 22879795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.